OngoingEUCTR 2015-003578-34

An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression

This ongoing study focuses on depression and currently lists sites or participation links in Germany, United Kingdom, Belgium, Spain, Poland, Hungary, Czech Republic, Slovakia, Lithuania, Austria, Finland, Bulgaria, Italy, View results.

DepressionOther

In plain English

Key information made simple

This study is looking at whether ESKETAMINE Esketamine (for (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone) can help people with Treatment-resistant Major Depression or Elderly. Participants receive the study medicine ESKETAMINE Esketamine (for (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone) and complete study visits and assessments. Taking part may give some people access to ESKETAMINE Esketamine (for (S)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone), but direct benefit is not guaranteed.

What to expect

Your next step

The official record does not clearly describe the visit format, so the practical details are best checked directly in the source. Participation appears to involve study activities and follow-up chosen by the research team. The main fit and exclusions are best confirmed in the eligibility section of the official record. The phase details are not clearly stated here.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Open source record

Need help deciding?

Ask HopeStage to review this study with me

This form records your interest so HopeStage can follow up with practical guidance. It is not a medical eligibility decision and it does not guarantee a study spot.

Study reference: EUCTR 2015-003578-34. We only ask for your email here. HopeStage can help you review the study, but this is not a medical eligibility decision.

In practice

For you

Taking part may help improve understanding of your condition.

It requires regular follow-up, often through questionnaires or interviews.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com